Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel Phase III Data Shows Significant Improvement In Pediatric Psoriasis

This article was originally published in The Pink Sheet Daily

Executive Summary

Enbrel could be the first biologic to treat pediatric patients' chronic moderate to severe plaque psoriasis.

You may also be interested in...



FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis

Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.

FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis

Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.

Enbrel “Black Box” Under Consideration By FDA, Amgen Execs Say

Amgen also has received two federal subpoenas related to its products, the firm discloses.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel